Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
Lower objective SES was associated with poorer performance on all cognitive domains: episodic memory (β = 0.115, p = 0.003), executive function (β = 0.210, p 0.05).
Why it matters
This study found that lower objective socioeconomic status was linked to worse performance across all cognitive domains in cognitively normal older adults. It does not test any treatment, cure, or prevention for Alzheimer's disease.
-
172 patients with symptomatic prion disease were identified. 165 (94.8%) patients experienced ≥1 symptom/sign likely to benefit from palliative care, yet only 113 (65.7%) patients accessed palliative care resources during the illness course (hospice care: 39.7%; palliative care consultation: 14.9% inpatient, 6.9% outpatient; both: 3.4%).
Why it matters
This study found that 94.8% of patients with symptomatic prion disease experienced at least one symptom likely to benefit from palliative care, yet only 65.7% accessed palliative care resources, most commonly because the diagnosing clinician did not refer them. It highlights an opportunity to enhance care by promoting early access to palliative care resources that may support symptom management.
-
Linear regression models showed that higher community deprivation on the ADI was associated with greater WMH volume, independently of age, sex, years of education, smoking, and time between study visits (beta=0.11, p =.028).
Why it matters
This study found that higher community deprivation on the Area Deprivation Index was associated with greater white matter hyperintensity volume, largely independent of blood pressure, cardiometabolic risk, and systemic inflammation. The authors call for future work to understand pathways linking residential environments to brain health, so no treatment, cure, or prevention is established.
-
Mild cognitive impairment (MCI) represents a heterogeneous state between normal aging and dementia, with varied transition pathways.
Why it matters
This study of 756 ADNI participants found that higher education, larger hippocampal volume, and lower daily functional impairment were associated with reversion from mild cognitive impairment to normal cognition, while APOE ε4, poorer memory, and greater brain atrophy predicted progression. These findings identify factors linked to MCI transition pathways but do not test a treatment, cure, or prevention.
-
Dementia significantly impacts cognitive, behavioral, and functional abilities, creating challenges for both individuals and caregivers.
Why it matters
This review of 32 recent publications found that technologies can support people with dementia and their caregivers by promoting independence, social engagement, and emotional and cognitive support. It identified gaps in addressing the needs of people with early-stage dementia and a lack of individualized support.
-
Neighborhood deprivation was associated with poorer cognition (r = 0.36, p < 0.001), greater prevalence of modifiable risk factors (r = 0.36, p < 0.001), and greater SVD burden (β = 0.18, p = 0.008).
Why it matters
This study found that neighborhood deprivation was linked to poorer cognition in midlife adults, possibly through modifiable vascular risk factors and small vessel disease. The mediation was seen only for hypertensive small vessel disease, not for cerebral amyloid angiopathy-related small vessel disease.
-
all-cause mortality, stroke recurrence, cognition, and C-reactive protein (CRP).
Why it matters
This meta-analysis found that statin therapy after ischemic stroke significantly reduced all-cause mortality and was associated with a lower risk of post-stroke dementia but not post-stroke cognitive impairment overall. The findings support statins for secondary prevention after stroke, but they concern stroke-related cognitive outcomes rather than Alzheimer's disease specifically.
-
Four themes emerged: layered caregiving burden, cultural strain and emotional dissonance, dual emotional experiences of caregiving, and coping strategies and unmet needs.
Why it matters
This qualitative study of dementia family caregivers in China describes chronic fatigue, disrupted family roles, social isolation, and filial piety acting as both a protective and harmful force. It points to culturally tailored support such as dementia education, respite services, and peer or counseling support, but it did not test whether these interventions work.
-
Change in QoL (decreased, maintained or improved) was determined using a cross-tabulation test.
Why it matters
In this cost analysis of the MedWalk trial, a Mediterranean diet and walking program cost about $2695 AUD per participant, but quality of life scores did not differ significantly between groups after 12 months. The study reports costs and quality of life outcomes rather than a clear cognitive benefit.
-
BackgroundClinician communication at the time of a dementia diagnosis often inadequately addresses patient and caregiver needs.
Why it matters
This qualitative study of patients with dementia and caregivers identified themes about diagnostic disclosure communication, including the emotional impact of sudden or unsupported disclosures and distress from ambiguous diagnoses. It concerns communication experiences and does not test any treatment, cure, or prevention for Alzheimer's disease.
-
This review seeks to understand what urban planning and management can do to reduce disaster risk and help cities adapt to the impacts of climate change.
Why it matters
This review is about urban planning for disaster risk reduction and climate change adaptation, not Alzheimer's disease, so it provides no information on Alzheimer's treatment, cure or prevention. It discusses how the concept of resilience links disaster risk reduction, sustainability and climate adaptation.
-
Dementia is a growing problem of global relevance, currently affecting over 55 million people worldwide.
Why it matters
This review describes the types of sleep disorders seen in neurodegenerative diseases including Alzheimer's disease, and notes a bidirectional relationship in which disrupted sleep can worsen neuropsychiatric symptoms and vice versa. It summarizes treatment strategies for sleep disturbances but does not report that treating sleep disorders cures or prevents Alzheimer's disease.
-
In the overall cohort (28 403 risperidone users and 136 324 mtatched controls), risperidone was associated with increased risk of stroke (adjusted hazard ratio: 1.28; 95% CI: 1.20-1.37).
Why it matters
In this population-based matched cohort, risperidone use in people with dementia was associated with a 28% increased risk of stroke, and this risk was higher in those with prior cardiovascular disease or stroke. The findings may help communicate risk and support more judicious prescribing.
-
Many medical and epidemiological studies use multivariable regression to test whether several independent variables (exposures) are causal determinants of a health outcome.
Why it matters
This paper argues that the common 'factors associated with' study design, which labels variables as risk factors based on regression results, is flawed and can produce implausible findings. It recommends abandoning this method, which means many reported dementia risk factors from such studies should be treated with caution.
-
Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE), Neuropsychiatric Inventory Questionnaire (NPI-Q), and Clinical Dementia Rating (CDR) scale plus National Alzheimer's Coordinating Center-Frontotemporal Lobar Degeneration module (NACC-FTLD).
Why it matters
In this study, markers of cerebral small vessel disease had a greater clinical impact in early-onset than late-onset dementia, with white matter hyperintensity volume predicting functional decline in early-onset patients. These findings support early detection of small vessel disease in younger people with dementia, but they do not test a treatment.
-
Targeted interventions, as enhanced training and improved support systems, are essential to address these disparities and better support GPs.
Why it matters
This survey found that rural general practitioners in Kazakhstan were less likely to consider early dementia diagnosis valuable and faced more challenges in dementia care compared to urban general practitioners. It does not test a treatment or prevention for Alzheimer's disease.
-
The project is expected to generate evidence on the effectiveness, feasibility, and cost-effectiveness of multidomain interventions implemented across diverse real-world settings, including community, hospital, and long-term care.
Why it matters
This describes a research program expected to generate evidence on multidomain interventions and technology-assisted strategies for frailty and cognitive decline. It reports no results yet and cannot show whether any approach prevents or treats Alzheimer's disease.
-
The presented results suggest the suitability of ecological handwriting analysis for the all-around monitoring of MCI, from early screening to disease progression evaluation.
Why it matters
This work suggests handwriting analysis could help screen for and track mild cognitive impairment, but it does not test any treatment, cure or prevention. The findings are preliminary and based on a recruited sample, so more research is needed before this could be used in care.
-
Identifying strategies to enhance patient engagement and to control healthcare costs promotes a responsive and efficient healthcare system.
Why it matters
This cost prediction study estimated that receiving advance care planning by telehealth was linked to lower hospital costs for people with dementia, with differences by race. It does not test any treatment, cure or prevention.
-
An assessment of the value of lecanemab for patients living with Alzheimer's disease (AD) and their care partners provides them and their health-care providers important information for deciding treatment initiation.
Why it matters
This modeling study estimated the long-term health and economic value of lecanemab for people with Alzheimer's disease and their care partners, finding reduced medical costs, fewer caregiving hours, and improved quality of life over time. It is a simulation based on trial and cohort data, not a new clinical trial of cure or prevention.
-
Cardiovascular disease (CVD) and cancer remain the leading causes of mortality in the United States, where poor diet has surpassed smoking as the leading risk factor for death, and life expectancy has hit a plateau as CVD mortality has stagnated over the past decade.
Why it matters
This review is about diet in the prevention of cardiovascular disease and cancer, not Alzheimer's disease, so it provides no information on Alzheimer's treatment, cure or prevention. It discusses observational and emerging trial data on whole-food plant-based diets for those conditions.
-
41/100
Age-related hearing loss (ARHL) has emerged as a significant and potentially modifiable risk factor for neurodegenerative disorders, including Alzheimer's disease.
Why it matters
This review describes age-related hearing loss as a potentially modifiable risk factor for neurodegenerative disorders including Alzheimer's disease, and discusses possible mechanisms and inequities in hearing care. It outlines research priorities rather than testing any treatment or prevention, so it does not show that treating hearing loss prevents dementia.
-
= 1), and three caregivers. Five key themes were identified, including ease of use, wearability, usefulness, transparency, and behavioral intention.
Why it matters
People with mild cognitive impairment and caregivers gave feedback on wearable devices for early detection of dementia-causing diseases, noting issues with ease of use, transparency and data concerns. This is about acceptability and design, not about treating, curing or preventing dementia.
-
People with dementia (PWD) are frequently exposed to polypharmacy and potentially inappropriate medication use, in which the risks of medication use outweigh the benefits or the medication is not aligned with treatment goals.
Why it matters
This article reviews the risks of polypharmacy in people with dementia and the evidence on deprescribing, and provides a roadmap for stopping unnecessary or potentially inappropriate medications. It addresses improving care and avoiding harm, not curing or preventing dementia.
-
Underreporters showed lower cognitive performance (p = 0.021), which did not translate into higher self-report SMC (p = 0.092).
Why it matters
In this longitudinal study of 128 older adults with MCI, underreporting of memory deficits compared with informant reports was associated with a 4.31-fold increased risk of conversion to dementia. The findings suggest that disagreement between self- and informant-reported memory complaints can help predict disease progression, but no treatment was tested.
From across this topic
10 of the 7,967 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Acupuncture for amnestic mild cognitive impairment: A pilot multicenter, randomized, parallel controlled trial
- Evaluation of a Japanese version of the Mini-Mental State Examination in elderly persons
- The continuous learning needs of personal support workers who care for people living with dementia in long-term care
- Interventions for preventing delirium in hospitalised non-ICU patients
- Incidental covert cerebral small vessel disease: Detection and management
- Dietary Patterns and Cognitive Decline: key features for prevention
- Comorbidity in dementia: update of an ongoing autopsy study
- Extreme Heat and Hospitalization Among Older Persons With Alzheimer Disease and Related Dementias
- Sex Differences in Cognitive Decline Among US Adults
- Cognitive impairment and outcomes in older adult survivors of acute myocardial infarction: findings from the translational research investigating underlying disparities in acute myocardial infarction patients' health status registry